We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ahead of Insulet (PODD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Read MoreHide Full Article
The upcoming report from Insulet (PODD - Free Report) is expected to reveal quarterly earnings of $1.13 per share, indicating an increase of 25.6% compared to the year-ago period. Analysts forecast revenues of $676.39 million, representing an increase of 24.4% year over year.
The consensus EPS estimate for the quarter has been revised 0.7% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Insulet metrics that are commonly tracked and projected by analysts on Wall Street.
The consensus estimate for 'Revenue- Total Omnipod' stands at $670.96 million. The estimate indicates a year-over-year change of +25.7%.
Analysts predict that the 'Revenue- Drug Delivery' will reach $2.14 million. The estimate indicates a year-over-year change of -79.2%.
The combined assessment of analysts suggests that 'Revenue- International Omnipod' will likely reach $187.32 million. The estimate points to a change of +35.7% from the year-ago quarter.
Analysts expect 'Revenue- U.S. Omnipod' to come in at $483.65 million. The estimate suggests a change of +22.3% year over year.
Shares of Insulet have experienced a change of +2.3% in the past month compared to the +2.1% move of the Zacks S&P 500 composite. With a Zacks Rank #2 (Buy), PODD is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Ahead of Insulet (PODD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
The upcoming report from Insulet (PODD - Free Report) is expected to reveal quarterly earnings of $1.13 per share, indicating an increase of 25.6% compared to the year-ago period. Analysts forecast revenues of $676.39 million, representing an increase of 24.4% year over year.
The consensus EPS estimate for the quarter has been revised 0.7% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Insulet metrics that are commonly tracked and projected by analysts on Wall Street.
The consensus estimate for 'Revenue- Total Omnipod' stands at $670.96 million. The estimate indicates a year-over-year change of +25.7%.
Analysts predict that the 'Revenue- Drug Delivery' will reach $2.14 million. The estimate indicates a year-over-year change of -79.2%.
The combined assessment of analysts suggests that 'Revenue- International Omnipod' will likely reach $187.32 million. The estimate points to a change of +35.7% from the year-ago quarter.
Analysts expect 'Revenue- U.S. Omnipod' to come in at $483.65 million. The estimate suggests a change of +22.3% year over year.
View all Key Company Metrics for Insulet here>>>Shares of Insulet have experienced a change of +2.3% in the past month compared to the +2.1% move of the Zacks S&P 500 composite. With a Zacks Rank #2 (Buy), PODD is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .